Dr. Toufigh Gordi to discuss the Selection of Appropriate Mathematical Modeling Techniques in Drug Development at 4th World PK/PD Summit

SAN CARLOS, CA, November 08, 2012

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Dr. Toufigh Gordi, President of PK/PD and Clinical Pharmacology Services, will present a talk at the 4th World PK/PD Summit on November 28, 2012, in Frankfort, Germany. The talk, entitled "Models and their Impact in the Drug Development Process", will focus on the different uses of mathematical modeling in drug development. Dr. Gordi will describe various models, including pharmacokinetic models, mechanistic pharmacodynamics models, and systems pharmacology models. He will discuss how mathematical modeling can be used to address different types of decisions throughout the preclinical and clinical stages of the drug development process.

"Understanding and applying the best model and the most appropriate use of mathematical modeling can add significant value to the drug development process," said Dr. Ron Beaver, Rosa's President and CEO.

"Quantitative analysis of the available data and systems models based on the best available knowledge can significantly increase our understanding of the observations and the underlying mechanism. Such an approach has the potential to radically improve the drug development process," said Dr. Toufigh Gordi, Rosa's President of PK/PD and Clinical Pharmacology Services.

Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit http://www.rosaandco.com.